兆科眼科-B(06622)：Tenpoint接获FDA在美国就BRIMOCHOL™ PF发出的批准

智通财经01-29

智通财经APP讯，兆科眼科-B(06622)发布公告，本公司的伙伴Tenpoint Therapeutics, Ltd.(Tenpoint)已接获美国食品药品监督管理局(FDA)批准商业化卡巴胆硷及酒石酸溴莫尼丁滴眼液(2.75%/0.1%)的监管批准。此滴眼液于临床试验期间名为BRIMOCHOL™ PF，在美国的商用名称将为YUVEZZI™，作为用于治疗老花眼的创新药物。此批准在Tenpoint...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2607082586?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-29 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607082586","market":"fut","top_or_hot":-1,"title":"兆科眼科-B(06622)：Tenpoint接获FDA在美国就BRIMOCHOL™ PF发出的批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，兆科眼科-B(06622)发布公告，本公司的伙伴Tenpoint Therapeutics, Ltd.(Tenpoint)已接获美国食品药品监督管理局(FDA)批准商业化卡巴胆硷及酒石酸溴莫尼丁滴眼液(2.75%/0.1%)的监管批准。此滴眼液于临床试验期间名为BRIMOCHOL™ PF，在美国的商用名称将为YUVEZZI™，作为用于治疗老花眼的创新药物。此批准在Tenpoint...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1399367.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>兆科眼科-B(06622)：Tenpoint接获FDA在美国就BRIMOCHOL™ PF发出的批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n兆科眼科-B(06622)：Tenpoint接获FDA在美国就BRIMOCHOL™ PF发出的批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-29 20:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1399367.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，兆科眼科-B(06622)发布公告，本公司的伙伴Tenpoint Therapeutics, Ltd.(Tenpoint)已接获美国食品药品监督管理局(FDA)批准商业化卡巴胆硷及酒石酸溴莫尼丁滴眼液(2.75%/0.1%)的监管批准。此滴眼液于临床试验期间名为BRIMOCHOL™ PF，在美国的商用名称将为YUVEZZI™，作为用于治疗老花眼的创新药物。此批准在Tenpoint...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1399367.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1399367.html","article_id":"2607082586","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607082586","pubTimestamp":1769690182,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"此滴眼液于临床试验期间名为BRIMOCHOL PF，在美国的商用名称将为YUVEZZI，作为用于治疗老花眼的创新药物。此批准在Tenpoint成功完成第3期临床试验后取得。此外，在BRIO II研究监测的逾72000个治疗日中，BRIMOCHOL PF耐受性良好，未观察到治疗相关的严重不良事件。在BRIO II研究中，接受BRIMOCHOL PF的受试者出现眼部充血不良事件的报告率低于单独接受卡巴胆硷的受试者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","06622":"兆科眼科-B","BK1191":"制药","BK1574":"生物医药B类股","BK1587":"次新股"},"translate_title":"Zhaoke Ophthalmology-B (06622): Tenpoint received FDA's request for BRIMOCHOL in the US ™ Approval issued by PF","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1.5},"content_text":"智通财经APP讯，兆科眼科-B(06622)发布公告，本公司的伙伴Tenpoint Therapeutics, Ltd.(Tenpoint)已接获美国食品药品监督管理局(FDA)批准商业化卡巴胆硷及酒石酸溴莫尼丁滴眼液(2.75%/0.1%)的监管批准。此滴眼液于临床试验期间名为BRIMOCHOL™ PF，在美国的商用名称将为YUVEZZI™，作为用于治疗老花眼的创新药物。此批准在Tenpoint成功完成第3期临床试验后取得。第一次的关键第3期BRIO I研究展示出组合疗法对比个别单一疗法活性药复合物较具优势。于第二次的安慰剂对照第3期BRIO II研究，BRIMOCHOL™ PF达到所有主要近距离视力的改善研究终点，统计上双眼未矫正近视力(BUCNVA)显著提升三行或以上，而双眼未矫正远视力(BUCDVA)未有一行或以上下降。此外，在BRIO II研究监测的逾72000个治疗日中，BRIMOCHOL™ PF耐受性良好，未观察到治疗相关的严重不良事件。在该药物的临床试验中，眼部发红并非常见报告的副作用。于BRIO I及BRIO II研究中，眼部充血(眼部发红)不良事件的报告率低。在BRIO II研究中，接受BRIMOCHOL™ PF的受试者出现眼部充血(眼睛发红)不良事件的报告率(2.8%)低于单独接受卡巴胆硷的受试者(10.7%)。就兆科眼科而言，此批准乃其制定商业化策略前的强大催化剂。本公司已为 BRIMOCHOL™ PF建立伙伴关系网络，现时包罗亚太区(包括南韩、澳洲、新西兰、泰国、印尼、台湾╱香港╱澳门地区、新加坡及越南)及中东内的八名商业伙伴。凭借FDA的认可，兆科预料可加快该药物面世，标志着一项重要的全球里程碑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607082586","isCrawlerRequest":true}